Harmony Biosciences
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 weeks.
- Its last 5 Sell calls were followed by a 4% average decline over the next quarter.
- Recent price momentum is -8.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 11.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 08:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation A
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 10.8x | Better than 76% |
| Forward P/E | 8.0x | Better than 90% |
| Price / Sales | 2.0x | Better than 57% |
| P/E vs own 5-yr range | 17th pctl | Better than 86% |
Growth B+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 25.6% | Better than 87% |
| Net income CAGR (3Y) | -4.4% | Better than 34% |
| Free cash flow CAGR (3Y) | 34.1% | Better than 77% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 77.2% | Better than 88% |
| Operating margin | 24.0% | Better than 83% |
| Net margin | 18.3% | Better than 77% |
| Return on equity | 20.8% | Better than 79% |
| Return on invested capital | 16.4% | Better than 84% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -14.6% | Better than 41% |
| 6-month return | 8.1% | Better than 69% |
| 12-month return (ex latest month) | 5.3% | Better than 41% |
| Distance below 52-week high | 25.1% | Better than 51% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.6x | Better than 78% |
| Debt to assets | 12.9% | Better than 65% |
| Interest coverage | 15.7x | Better than 79% |
| Free cash flow / net income | 219.2% | Better than 80% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 62.5% | Better than 39% |
| Upside to average target | 45.8% | Better than 63% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 32.98
- Open
- 32.68
- Day range
- 32.51 - 33.43
- Avg price
- 32.83
- Volume
- 582.64K
- Turnover
- 19.13M
- Turnover ratei
- 1.11%
- Volume ratioi
- 0.82
- Amplitudei
- 2.77%
- 52-week rangei
- 25.90 - 43.49
Valuation
- P/Ei
- 12.03
- P/E (TTM)i
- 10.79
- P/Bi
- 1.78
- EPSi
- 2.71
- Book value / shi
- 18.26
- Net profit
- 159.14M
- Net assets
- 1.07B
Share structure
- Market cap
- 1.91B
- Float capi
- 1.71B
- Shares out
- 58.72M
- Float sharesi
- 52.58M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2020-08-19
25.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-6.40M net over the window
Short interest
- Shares short
- 6.66M
- % of floati
- 11.44%
- Days to coveri
- 5.63
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Harmony Biosciences (HRMY)?
Harmony Biosciences last traded at 32.59. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Harmony Biosciences's market cap?
About 1.91B.
What is the P/E ratio of Harmony Biosciences?
The trailing twelve-month P/E is 10.79, below its own 5-year average of 20.44 — toward the bottom of its historical range (16.59% percentile). See the Valuation tab for the full history.
Does Harmony Biosciences pay a dividend?
Harmony Biosciences does not currently pay a regular dividend.
Is Harmony Biosciences a buy according to analysts?
The consensus of 8 analysts is a Buy rating, with an average 12-month price target of 47.50, which implies 45.8% upside from the current price. This is not investment advice.
What is Harmony Biosciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Harmony Biosciences a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 20:02:36 · For reference only, not investment advice and not tailored to your situation.
Harmony Biosciences discussion 0 comments